Pfizer (NYSE:PFE) Stock Price Down 1.1% – Here’s Why

Shares of Pfizer Inc. (NYSE:PFE) traded down 1.1% during trading on Friday. The company traded as low as $27.44 and last traded at $27.8080. Approximately 34,908,008 shares changed hands during mid-day trading, a decline of 14% from the average session volume of 40,713,457 shares. The stock had previously closed at $28.12.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: LITFULO delivers positive Phase 3 vitiligo results: Pfizer said its oral treatment ritlecitinib significantly improved facial and total-body repigmentation versus placebo in the TRANQUILLO and TRANQUILLO 2 Phase 3 trials. Positive patient-reported outcomes and the potential to expand LITFULO into a new indication could strengthen Pfizer’s immunology growth outlook. Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation
• Positive Sentiment: Tilrekimig advances toward late-stage development: The company reported that its Phase 2 atopic dermatitis study met its primary endpoint, with significantly more patients achieving at least a 75% reduction in disease severity than those receiving placebo. Pfizer plans Phase 3 studies in atopic dermatitis and asthma, potentially adding a meaningful future immunology asset to its pipeline. Pfizer’s Tilrekimig Shows Significant Skin Clearance
• Positive Sentiment: Breast-cancer trial reaches a milestone: Pfizer provided an update on the TACTIVE-U Sub-Study C Phase 3 trial involving a breast-cancer combination. The update supports continued development of the oncology portfolio, although the available report does not provide enough efficacy or regulatory detail to quantify the commercial impact. Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone
• Neutral Sentiment: Pipeline progress is important because Pfizer remains in transition: Analysts and financial commentary continue to highlight largely flat revenue, the decline in COVID-related sales and patent-loss pressure. Pfizer’s roughly 6% dividend yield may attract income investors, but future returns depend on successful launches and acquisitions translating into durable growth. Pfizer’s Dividend and Business Transition
• Negative Sentiment: Florida lawsuit adds legal overhang: Florida’s attorney general sued Pfizer and its chief executive over claims related to COVID-19 vaccine disclosures and risks. The allegations could create litigation costs, reputational damage and additional uncertainty around the company’s COVID-19 business.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PFE shares. BMO Capital Markets lowered their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Sunday, September 13th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Finally, Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.39.

Pfizer Stock Performance

The company has a market capitalization of $158.50 billion, a P/E ratio of 36.59, a PEG ratio of 1.92 and a beta of 0.32. The stock’s fifty day moving average price is $27.34 and its 200-day moving average price is $26.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. First Financial Bank Trust Division raised its stake in Pfizer by 3.1% in the 3rd quarter. First Financial Bank Trust Division now owns 170,089 shares of the biopharmaceutical company’s stock valued at $4,851,000 after acquiring an additional 5,191 shares during the period. QRG Capital Management Inc. boosted its position in Pfizer by 5.8% during the second quarter. QRG Capital Management Inc. now owns 902,308 shares of the biopharmaceutical company’s stock worth $21,728,000 after purchasing an additional 49,804 shares during the period. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Pfizer by 16.0% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 179,745 shares of the biopharmaceutical company’s stock valued at $4,328,000 after purchasing an additional 24,744 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Pfizer by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 9,513,242 shares of the biopharmaceutical company’s stock valued at $229,078,000 after purchasing an additional 167,641 shares during the last quarter. Finally, Andra AP fonden lifted its stake in shares of Pfizer by 196.6% during the 2nd quarter. Andra AP fonden now owns 728,273 shares of the biopharmaceutical company’s stock worth $17,537,000 after buying an additional 482,700 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.